{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T14:38:23Z","timestamp":1782225503269,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:00:00Z","timestamp":1540339200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"University of Cincinnati Brain Tumor Center Molecular Therapeutics Program"},{"name":"University of Cincinnati Neuroscience Institute"},{"name":"University of Cincinnat Technology Commercialization Accelerator"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00280-018-3705-6","type":"journal-article","created":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T12:13:14Z","timestamp":1540383194000},"page":"81-89","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats"],"prefix":"10.1007","volume":"83","author":[{"given":"Priyanka","family":"Arora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney Huff","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Gudelsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biplab","family":"DasGupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3001-1603","authenticated-orcid":false,"given":"Pankaj B.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,24]]},"reference":[{"issue":"suppl_5","key":"3705_CR1","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/nox158","volume":"19","author":"QT Ostrom","year":"2017","unstructured":"Ostrom QT, Gittleman H, Liao P et al (2017) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united states in 2010\u20132014. Neuro Oncol 19(suppl_5):v1\u2013v88","journal-title":"Neuro Oncol"},{"key":"3705_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000464374","volume":"30","author":"QT Ostrom","year":"2018","unstructured":"Ostrom QT, Gittleman H, Stetson L, Virk S, Barnholtz-Sloan JS (2018) Epidemiology of intracranial gliomas. Prog Neurol Surg 30:1\u201311","journal-title":"Prog Neurol Surg"},{"issue":"8","key":"3705_CR3","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40263-017-0454-8","volume":"31","author":"E Franceschi","year":"2017","unstructured":"Franceschi E, Minichillo S, Brandes AA (2017) Pharmacotherapy of glioblastoma: Established treatments and emerging concepts. CNS Drugs 31(8):675\u2013684","journal-title":"CNS Drugs"},{"key":"3705_CR4","doi-asserted-by":"publisher","first-page":"64","DOI":"10.4103\/2152-7806.137196","volume":"5","author":"TA Wilson","year":"2014","unstructured":"Wilson TA, Karajannis MA, Harter DH (2014) Glioblastoma multiforme: state of the art and future therapeutics. Surg Neurol Int 5:64\u20137806.132138","journal-title":"Surg Neurol Int"},{"key":"3705_CR5","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.125","author":"E Franceschi","year":"2015","unstructured":"Franceschi E, Bartolotti M, Brandes AA (2015) Bevacizumab in recurrent glioblastoma: Open issues. Future Oncol. \n                    https:\/\/doi.org\/10.2217\/fon.15.125","journal-title":"Future Oncol"},{"issue":"9","key":"3705_CR6","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1002\/jps.23600","volume":"102","author":"M Miyajima","year":"2013","unstructured":"Miyajima M, Kusuhara H, Takahashi K et al (2013) Investigation of the effect of active efflux at the blood-brain barrier on the distribution of nonsteroidal aromatase inhibitors in the central nervous system. J Pharm Sci 102(9):3309\u20133319","journal-title":"J Pharm Sci"},{"key":"3705_CR7","doi-asserted-by":"publisher","unstructured":"Wijaya J, Fukuda Y, Schuetz JD (2017) Obstacles to brain tumor therapy: Key ABC transporters. Int J Mol Sci 18(12):\n                    https:\/\/doi.org\/10.3390\/ijms18122544","DOI":"10.3390\/ijms18122544"},{"issue":"3","key":"3705_CR8","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.bbrc.2015.06.137","volume":"468","author":"SS Kim","year":"2015","unstructured":"Kim SS, Harford JB, Pirollo KF, Chang EH (2015) Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine. Biochem Biophys Res Commun 468(3):485\u2013489","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"3705_CR9","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/00000421-200308001-00002","volume":"26","author":"PE Lonning","year":"2003","unstructured":"Lonning PE, Geisler J, Bhatnager A (2003) Development of aromatase inhibitors and their pharmacologic profile. Am J Clin Oncol 26(4):S3\u2013S8","journal-title":"Am J Clin Oncol"},{"issue":"Suppl 5","key":"3705_CR10","first-page":"v20","volume":"17","author":"N Dave","year":"2015","unstructured":"Dave N, Sengaonkar V, Chow LML, Kendler A, LaSance K, Desai PB (2015) ATPS-13 Aromatase expression in high grade gliomas: a potential new target for therapy. Neurooncol 17(Suppl 5):v20\u2013v21","journal-title":"Neurooncol"},{"issue":"2","key":"3705_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11060-014-1509-z","volume":"119","author":"JM Duenas Jimenez","year":"2014","unstructured":"Duenas Jimenez JM, Candanedo Arellano A, Santerre A et al (2014) Aromatase and estrogen receptor alpha mRNA expression as prognostic biomarkers in patients with astrocytomas. J Neurooncol 119(2):275\u2013284","journal-title":"J Neurooncol"},{"issue":"2","key":"3705_CR12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00280-013-2205-y","volume":"72","author":"N Dave","year":"2013","unstructured":"Dave N, Gudelsky GA, Desai PB (2013) The pharmacokinetics of letrozole in brain and brain tumor in rats with orthotopically implanted C6 glioma, assessed using intracerebral microdialysis. Cancer Chemother Pharmacol 72(2):349\u2013357","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"3705_CR13","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1158\/1535-7163.MCT-14-0743","volume":"14","author":"N Dave","year":"2015","unstructured":"Dave N, Chow LM, Gudelsky GA, LaSance K, Qi X, Desai PB (2015) Preclinical pharmacological evaluation of letrozole as a novel treatment for gliomas. Mol Cancer Ther 14(4):857\u2013864","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"3705_CR14","doi-asserted-by":"publisher","first-page":"16605","DOI":"10.18632\/oncotarget.15073","volume":"8","author":"A Tivnan","year":"2017","unstructured":"Tivnan A, Heilinger T, Ramsey JM et al (2017) Anti-GD2-ch14.18\/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells. Oncotarget 8(10):16605\u201316620","journal-title":"Oncotarget"},{"issue":"3","key":"3705_CR15","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1248\/cpb.c17-00789","volume":"66","author":"S Okada","year":"2018","unstructured":"Okada S, Vaeteewoottacharn K, Kariya R (2018) Establishment of a patient-derived tumor xenograft model and application for precision cancer medicine. Chem Pharm Bull (Tokyo) 66(3):225\u2013230","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"3705_CR16","doi-asserted-by":"publisher","first-page":"6153","DOI":"10.1158\/0008-5472.CAN-16-1260","volume":"76","author":"JJ Morton","year":"2016","unstructured":"Morton JJ, Bird G, Refaeli Y, Jimeno A (2016) Humanized Mouse Xenograft Models: Narrowing the Tumor-Microenvironment Gap. Cancer Res 76:6153\u20136158","journal-title":"Cancer Res"},{"key":"3705_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.canlet.2013.10.015","volume":"344","author":"Q Zhou","year":"2014","unstructured":"Zhou Q, Facciponte J, Jin M, Shen Q, Lin Q (2014) Humanized NOD-SCID IL2rg\u2212\/\u2212 mice as a preclinical model for cancer research and its potential use for individualized cancer therapies. Cancer Lett 344:13\u201319","journal-title":"Cancer Lett"},{"issue":"2","key":"3705_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00280-007-0464-1","volume":"61","author":"SK Apparaju","year":"2008","unstructured":"Apparaju SK, Gudelsky GA, Desai PB (2008) Pharmacokinetics of gemcitabine in tumor and non-tumor extracellular fluid of brain: an in vivo assessment in rats employing intracerebral microdialysis. Cancer Chemother Pharmacol 61(2):223\u2013229","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"3705_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0165-0270(80)90021-7","volume":"3","author":"G Paxinos","year":"1980","unstructured":"Paxinos G, Watson CR, Emson PC (1980) Ache-stained horizontal sections of the rat brain in stereotaxic coordinates. J Neurosci Methods 3(2):129\u2013149","journal-title":"J Neurosci Methods"},{"issue":"6","key":"3705_CR20","first-page":"1347","volume":"69","author":"E Gilant","year":"2012","unstructured":"Gilant E, Kaza M, Szlagowska A, Serafin-Byczak K, Rudzki PJ (2012) Validated HPLC method for determination of temozolomide in human plasma. Acta Pol Pharm 69(6):1347\u20131355","journal-title":"Acta Pol Pharm"},{"issue":"2","key":"3705_CR21","first-page":"309","volume":"5","author":"SD Baker","year":"1999","unstructured":"Baker SD, Wirth M, Statkevich P et al (1999) Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 5(2):309\u2013317","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3705_CR22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1080\/00498250410001685737","volume":"34","author":"L Reyderman","year":"2004","unstructured":"Reyderman L, Statkevich P, Thonoor CM, Patrick J, Batra VK, Wirth M (2004) Disposition and pharmacokinetics of temozolomide in rat. Xenobiotica 34(5):487\u2013500","journal-title":"Xenobiotica"},{"issue":"8","key":"3705_CR23","first-page":"680","volume":"21","author":"XD Liu","year":"2000","unstructured":"Liu XD, Xie L, Zhong Y, Li CX (2000) Gender difference in letrozole pharmacokinetics in rats. Acta Pharmacol Sin 21(8):680\u2013684","journal-title":"Acta Pharmacol Sin"},{"issue":"9","key":"3705_CR24","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1002\/cncr.10908","volume":"95","author":"AU Buzdar","year":"2002","unstructured":"Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM (2002) An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 95(9):2006\u20132016","journal-title":"Cancer"},{"issue":"1 Pt 2","key":"3705_CR25","first-page":"468S","volume":"9","author":"AU Buzdar","year":"2003","unstructured":"Buzdar AU (2003) Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. Clin Cancer Res 9(1 Pt 2):468S\u2013468S72S","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3705_CR26","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1211\/jpp.59.6.0006","volume":"59","author":"MF Wempe","year":"2007","unstructured":"Wempe MF, Buchanan CM, Buchanan NL et al (2007) Pharmacokinetics of letrozole in male and female rats: Influence of complexation with hydroxybutenyl-beta cyclodextrin. J Pharm Pharmacol 59(6):795\u2013802","journal-title":"J Pharm Pharmacol"},{"key":"3705_CR27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.mce.2016.11.005","volume":"440","author":"A Kalam","year":"2017","unstructured":"Kalam A, Talegaonkar S, Vohora D (2017) Effects of raloxifene against letrozole-induced bone loss in chemically-induced model of menopause in mice. Mol Cell Endocrinol 440:34\u201343","journal-title":"Mol Cell Endocrinol"},{"issue":"11","key":"3705_CR28","doi-asserted-by":"publisher","first-page":"795","DOI":"10.3109\/00498250903171395","volume":"39","author":"K Murai","year":"2009","unstructured":"Murai K, Yamazaki H, Nakagawa K, Kawai R, Kamataki T (2009) Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. Xenobiotica 39(11):795\u2013802","journal-title":"Xenobiotica"},{"issue":"1","key":"3705_CR29","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13104-017-2435-x","volume":"10","author":"KS Poca","year":"2017","unstructured":"Poca KS, Parente TE, Chagas LF et al (2017) Interstrain differences in the expression and activity of Cyp2a5 in the mouse liver. BMC Res Notes 10(1):125\u2013017-2435-x","journal-title":"BMC Res Notes"},{"issue":"14","key":"3705_CR30","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1158\/1078-0432.CCR-07-0658","volume":"13","author":"Q Zhou","year":"2007","unstructured":"Zhou Q, Guo P, Kruh GD, Vicini P, Wang X, Gallo JM (2007) Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition. Clin Cancer Res 13(14):4271\u20134279","journal-title":"Clin Cancer Res"},{"issue":"22","key":"3705_CR31","doi-asserted-by":"publisher","first-page":"7092","DOI":"10.1158\/1078-0432.CCR-09-1349","volume":"15","author":"J Portnow","year":"2009","unstructured":"Portnow J, Badie B, Chen M, Liu A, Blanchard S, Synold TW (2009) The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: Potential implications for the current approach to chemoradiation. Clin Cancer Res 15(22):7092\u20137098","journal-title":"Clin Cancer Res"},{"issue":"11","key":"3705_CR32","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.1158\/1078-0432.CCR-03-0807","volume":"10","author":"S Ostermann","year":"2004","unstructured":"Ostermann S, Csajka C, Buclin T et al (2004) Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 10(11):3728\u20133736","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3705_CR33","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1634\/theoncologist.5-2-144","volume":"5","author":"SS Agarwala","year":"2000","unstructured":"Agarwala SS, Kirkwood JM (2000) Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 5(2):144\u2013151","journal-title":"Oncologist"},{"issue":"1","key":"3705_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.canlet.2015.07.013","volume":"367","author":"JL Munoz","year":"2015","unstructured":"Munoz JL, Walker ND, Scotto KW, Rameshwar P (2015) Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells. Cancer Lett 367(1):69\u201375","journal-title":"Cancer Lett"},{"key":"3705_CR35","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/annonc\/mdn548","volume":"20","author":"M Schaich","year":"2009","unstructured":"Schaich M, Kestel L, Pfirrmann M, Robel K, Illmer T, Kramer M, Dill C, Ehninger G, Schackert G, Krex D (2009) A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann Oncol 20:175\u2013181","journal-title":"Ann Oncol"},{"key":"3705_CR36","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.neo.2018.05.001","volume":"20","author":"MC Gooijer de","year":"2018","unstructured":"de Gooijer MC, de Vries NA, Buckle T, Buil LCM, Beijnen JH, Boogerd W, van Tellingen O (2018) Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2. Neoplasia 20:710\u2013720","journal-title":"Neoplasia"},{"key":"3705_CR37","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1021\/mp1001729","volume":"7","author":"A Mahringer","year":"2010","unstructured":"Mahringer A, Fricker G (2010) BCRP at the blood-brain barrier: genomic regulation by 17beta-estradiol. Mol Pharm 7:1835\u20131847","journal-title":"Mol Pharm"},{"key":"3705_CR38","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/jcbfm.2010.36","volume":"30","author":"AM Hartz","year":"2010","unstructured":"Hartz AM, Mahringer A, Miller DS, Bauer B (2010) 17-beta-Estradiol: a powerful modulator of blood-brain barrier BCRP activity. J Cereb Blood Flow Metab 30:1742\u20131755","journal-title":"J Cereb Blood Flow Metab"},{"key":"3705_CR39","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.marenvres.2004.03.015","volume":"58","author":"KM Kleinow","year":"2004","unstructured":"Kleinow KM, Hummelke GC, Zhang Y, Uppu P, Baillif C (2004) Inhibition of P-glycoprotein transport: a mechanism for endocrine disruption in the channel catfish? Mar Environ Res 58:205\u2013208","journal-title":"Mar Environ Res"},{"key":"3705_CR40","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.tips.2010.03.003","volume":"31","author":"DS Miller","year":"2010","unstructured":"Miller DS (2010) Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol Sci 31:246\u2013254","journal-title":"Trends Pharmacol Sci"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3705-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3705-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3705-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T19:58:14Z","timestamp":1571860694000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3705-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,24]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["3705"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3705-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,24]]},"assertion":[{"value":"17 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All the experiments were conducted in strict accordance with the Institutional Animal Care and Use Committee (IACUC)-approved protocols of Cincinnati Children\u2019s Hospital Medical Center (CCHMC) and University of Cincinnati and were performed as per the highest international standards of animal welfare outlined by the NIH\u2019s Guide for the Care and Use of Laboratory Animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}